:: Volume 19, Issue 3 (7-2021) ::
Int J Radiat Res 2021, 19(3): 749-753 Back to browse issues page
Successful treatment of a patient with an EGFR-mutated pulmonary adenocarcinoma and a history of uremia with erlotinib after gefitinib-induced kidney dysfunction: a case report
L. Zhou , Z. Chen
Respiratory ward 2, PCCM, Affiliated Hospital of Zunyi Medical University, Zunyi City, 563003, China , LinmeiZhou@outlook.com
Abstract:   (1845 Views)
A 48-year-old male patient with a history of uremia was diagnosed with pulmonary adenocarcinoma based on a computed tomography (CT) scan and biopsy. In addition, an epidermal growth factor receptor (EGFR) exon 19 deletion was identified by gene detection. Surgical treatment was not acceptable because of his poor physical condition, so he was treated with gefitinib. Kidney function deteriorated and the serum urea nitrogen and creatinine levels were increased. Two weeks after discontinuing treatment with gefitinib, kidney function gradually returned to normal and was treated with erlotinib. This is an unusual case involving a patient with EGFR-mutated pulmonary adenocarcinoma and a history of uremia who was successfully treated with erlotinib after gefitinib-induced kidney dysfunction.
Keywords: Epidermal growth factor receptor, pulmonary adenocarcinoma, Erlotinib, gefitinib, kidney function.
Full-Text [PDF 1995 kb]   (720 Downloads)    
Type of Study: Case Report | Subject: Radiobiology



XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 19, Issue 3 (7-2021) Back to browse issues page